Prothena (NASDAQ:PRTA - Get Free Report)'s stock had its "buy" rating reissued by research analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $14.00 target price on the biotechnology company's stock. HC Wainwright's price target suggests a potential upside of 76.77% from the stock's current price.
A number of other equities analysts have also recently commented on PRTA. Jefferies Financial Group cut Prothena from a "buy" rating to a "hold" rating and set a $6.00 price target for the company. in a report on Tuesday, May 27th. Bank of America restated an "underperform" rating on shares of Prothena in a research note on Wednesday, May 28th. Cantor Fitzgerald reiterated a "neutral" rating on shares of Prothena in a research report on Friday, June 20th. JMP Securities lowered their target price on Prothena from $78.00 to $29.00 and set a "market outperform" rating for the company in a report on Tuesday, May 27th. Finally, Oppenheimer lowered Prothena from an "outperform" rating to a "market perform" rating in a research note on Tuesday, May 27th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $30.25.
Check Out Our Latest Research Report on Prothena
Prothena Trading Up 12.7%
Shares of PRTA traded up $0.89 during midday trading on Tuesday, reaching $7.92. The stock had a trading volume of 3,106,590 shares, compared to its average volume of 838,497. The firm has a 50 day simple moving average of $6.07 and a 200-day simple moving average of $9.76. The firm has a market cap of $426.33 million, a PE ratio of -1.40 and a beta of -0.03. Prothena has a one year low of $4.32 and a one year high of $23.66.
Prothena (NASDAQ:PRTA - Get Free Report) last announced its earnings results on Monday, August 4th. The biotechnology company reported ($1.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.75). The business had revenue of $4.42 million during the quarter, compared to the consensus estimate of $5.36 million. Prothena had a negative net margin of 2,929.30% and a negative return on equity of 62.17%. As a group, research analysts forecast that Prothena will post -4.04 EPS for the current fiscal year.
Institutional Investors Weigh In On Prothena
Large investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. acquired a new stake in shares of Prothena during the 4th quarter worth approximately $182,000. American Century Companies Inc. boosted its position in shares of Prothena by 66.1% during the 4th quarter. American Century Companies Inc. now owns 30,399 shares of the biotechnology company's stock worth $421,000 after purchasing an additional 12,097 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Prothena in the 4th quarter valued at about $179,000. Vanguard Group Inc. increased its position in Prothena by 11.5% in the 4th quarter. Vanguard Group Inc. now owns 1,403,838 shares of the biotechnology company's stock valued at $19,443,000 after buying an additional 144,737 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Prothena by 93.7% during the 4th quarter. JPMorgan Chase & Co. now owns 387,350 shares of the biotechnology company's stock worth $5,365,000 after buying an additional 187,364 shares during the period. Institutional investors and hedge funds own 97.08% of the company's stock.
Prothena Company Profile
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Further Reading
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
